A team of researchers from the University of California, San Diego, developed a new computational strategy to find a molecule that shrinks glioblastoma (GBM) tumors by an average of 50 percent.
The study was led by Santosh Kesari, MD, Ph.D., director of Neuro-oncology at Moores UCSD Cancer Center, and was funded in-part by the American Brain Tumor Association’s Drug Discovery Grant. Using the Molecular Operation Environment (MOE) program, the team discovered that the molecule SKOG102 wedges itself between two transcription factors, or proteins, that enable GBM tumor growth.
By disrupting the association between transcription factor OLIG2 and another protein, SKOG102 was found to shrink human glioblastoma tumors grown in mouse models by an average of 50 percent.
Dr. Kesari comments, "While the initial pre-clinical findings are promising, it will be several years before a potential glioblastoma therapy can be tested in humans. SKOG102 must first undergo detailed pharmacodynamic, biophysical and mechanistic studies in order to better understand its efficacy and possible toxicity.”
To learn more about the study, click here.